Integrated Diagnostics Holdings (LSE:IDHC) reported sharply higher profits for the first half of 2026 and a net cash position, but its board decided against an additional distribution to shareholders. Why did the Egypt-focused diagnostics group choose to hold on to its cash, and how does that decision fit with its new ownership structure?

A diagnostics chain across Egypt and beyond

Integrated Diagnostics Holdings (IDH) runs pathology laboratories, radiology services and home-visit testing, mainly in Egypt, where it operates 793 branches. It also has operations in Jordan through Biolab, in Nigeria through Echo-Lab and in Saudi Arabia, while its Business in Sudan is largely closed because of conflict. Its shares have been listed on the London Stock Exchange since May 2015 and trade on the Main Market. The group reports in Egyptian pounds.

First-half growth

On 11 September 2026, IDH reported results for the six months to 30 June 2026. Revenue rose 37% to EGP 4.9 billion, EBITDA increased 38% to EGP 1.6 billion with a Margin of 33.9%, and net profit grew 47% to EGP 839 million. Basic Earnings Per Share were EGP 1.41, up from EGP 0.95. The company performed 23.6 million tests, up 20%, for 4.9 million patients, and revenue per test increased 14% to EGP 206. The branch network grew by 161 to 839 locations.

Egypt generated 85.9% of revenue, growing 41% to EGP 4,170 million. Jordan grew 9%, although its EBITDA margin eased to 26% from 29%. Nigeria returned to positive EBITDA, and Saudi Arabian revenue rose 199% from a small base. Radiology and radiotherapy revenue in Egypt climbed 79% to EGP 220 million, and house calls represented about 22% of Egyptian revenue. The contract segment generated 69% of group revenue and grew 41%, while walk-in patients accounted for 31% and grew 30%. Tests per patient rose to 4.9 from 4.6.

The Dividend decision and new controlling shareholder

IDH reported cash of EGP 1.9 billion, interest-bearing Debt of EGP 378 million and net cash of EGP 1.3 billion excluding leases. Even so, the board declined to make an additional distribution, saying it was prioritising cash preservation, Balance Sheet flexibility and Capital for expansion given regional geopolitical uncertainty. Capital Expenditure in the half was EGP 422 million, equal to 9% of revenue and mostly for branch openings, including EGP 50 million for Al-Borg Scan expansion.

The decision follows a change of control. On 23 June 2026, Hena Holdings, wholly owned by chief executive Dr Hend El-Sherbini and her mother, bought a 21.67% stake from Actis, lifting its holding to 49.62% and triggering a mandatory offer. The offer was declared unconditional on 29 July, and the half-year report states that it completed on 12 August 2026 with Hena holding 56.67%, leaving a 43.33% free float. Dr El-Sherbini described a good first-half performance, reflecting continued resilience of Demand across its markets.

Risks and points to watch

IDH's earnings are dominated by Egypt, so political and economic Volatility there, including currency movements, directly affect results reported in pounds and their value to sterling-based investors. Regulatory pricing changes, competition and Supply chain costs are further risks highlighted by the company. Expansion in Saudi Arabia and radiology requires Investment before returns are proven, and Sudan remains largely closed. With a controlling Shareholder now above 50%, minority holders have less influence over capital allocation, including future dividends.

Conclusion

IDH withheld an additional distribution because its board chose to preserve cash and keep flexibility for growth amid regional uncertainty, despite reporting solid profit growth and a net cash balance. The company now has a majority owner in its chief executive's family holding company. Future dividend decisions will indicate how the group balances expansion against returns to its remaining public shareholders.